Marshall Wace LLP Has $6.20 Million Holdings in CareDx, Inc (NASDAQ:CDNA)

Marshall Wace LLP trimmed its position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 21.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 289,457 shares of the company's stock after selling 78,973 shares during the quarter. Marshall Wace LLP owned approximately 0.54% of CareDx worth $6,197,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in CDNA. Lord Abbett & CO. LLC purchased a new position in shares of CareDx during the 3rd quarter worth about $10,873,000. Vanguard Group Inc. raised its holdings in shares of CareDx by 7.1% during the 4th quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company's stock valued at $104,047,000 after buying an additional 323,554 shares during the period. Next Century Growth Investors LLC purchased a new position in shares of CareDx in the fourth quarter valued at $4,705,000. Renaissance Technologies LLC grew its stake in shares of CareDx by 15.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,432,198 shares of the company's stock valued at $30,663,000 after acquiring an additional 196,298 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in CareDx by 25.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 875,197 shares of the company's stock worth $18,738,000 after purchasing an additional 178,304 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CDNA shares. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and dropped their target price for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. Stephens restated an "overweight" rating and set a $40.00 price objective on shares of CareDx in a research note on Thursday, February 27th. HC Wainwright lowered their target price on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. StockNews.com raised shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group dropped their price target on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $30.33.

CareDx Stock Down 2.0 %

CareDx stock traded down $0.37 during mid-day trading on Tuesday, hitting $17.89. 66,522 shares of the company's stock traded hands, compared to its average volume of 850,254. CareDx, Inc has a one year low of $7.61 and a one year high of $34.84. The company has a market cap of $991.29 million, a PE ratio of -6.62 and a beta of 2.18. The firm has a 50 day moving average price of $18.94 and a 200 day moving average price of $21.72.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million. On average, analysts expect that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.